1. Home
  2. Directory
  3. Iowa
  4. Denison
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1477545697

DR. KEITH A SCHRUNK OD
Prescription History 1477545697
Optometrist in Denison, IA


Quality Rating: 91.87 out of 100 score

NPI Status: Active since August 16, 2005

Contact Information

201 N MAIN ST
BOX 399
DENISON, IA
ZIP 51442
Phone: (712) 263-2020
Fax: (712) 263-4053

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. KEITH A SCHRUNK OD, an active Optometrist specialist practicing in Denison, IA. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 325 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 166 claims alone.

Medication Index

Dorzolamide Hcl

Generic Formulation: Dorzolamide HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 18
30-Day Fills 35.5
Days Supply 1,066
IA State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills73.3
Peer Average Days Supply2,188
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $420.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.39

State Avg Cost Per Claim

$25.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 166
30-Day Fills 311.9
Days Supply 9,025
IA State Average Benchmarks
Peer Average Claims122.0
Peer Average 30-Day Fills195.1
Peer Average Days Supply5,507
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.1% more claims than the standard regional baseline profile for IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,020.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.20

State Avg Cost Per Claim

$18.46

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Lumigan

Generic Formulation: BimatoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 48
30-Day Fills 76.3
Days Supply 2,149
IA State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills77.5
Peer Average Days Supply2,201
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $20,755.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$432.41

State Avg Cost Per Claim

$412.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

Bimatoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.

Pilocarpine Hcl

Generic Formulation: Pilocarpine HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 12
30-Day Fills 17.0
Days Supply 500
IA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills39.3
Peer Average Days Supply1,152
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.8% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $588.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$49.05

State Avg Cost Per Claim

$76.91

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

Therapeutic Applications

This medication is used to treat symptoms of dry mouth due to a certain immune disease (Sjogren's syndrome) or from saliva gland damage due to radiation treatments of the head/neck for cancer. Pilocarpine belongs to a class of drugs known as cholinergic agonists. It works by stimulating certain nerves to increase the amount of saliva you produce, making it easier and more comfortable to speak and swallow.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 26
30-Day Fills 38.0
Days Supply 1,140
IA State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills45.9
Peer Average Days Supply1,317
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $26,058.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,002.25

State Avg Cost Per Claim

$942.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Simbrinza

Generic Formulation: Brinzolamide/Brimonidine TartSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 21.3
Days Supply 550
IA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills31.3
Peer Average Days Supply889
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,978.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$262.01

State Avg Cost Per Claim

$236.67

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two medications used to treat high pressure in the eye due to glaucoma (open-angle glaucoma-type) or a certain other eye disease (ocular hypertension). Lowering high pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This product contains brinzolamide and brimonidine. These two medications work together to decrease the amount of fluid within the eye. Brinzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors. Brimonidine belongs to a class of drugs known as alpha agonists. This product is not recommended for use in children younger than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 31.3
Days Supply 938
IA State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills115.5
Peer Average Days Supply3,408
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.2% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $804.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$47.33

State Avg Cost Per Claim

$20.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Vyzulta

Generic Formulation: Latanoprostene BunodSpecialty: Optometry
Provider Metrics Summary
Total Claims 19
30-Day Fills 23.0
Days Supply 657
IA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills61.5
Peer Average Days Supply1,770
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.5% less volume than the regional standard for practitioners inside IA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,340.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$333.73

State Avg Cost Per Claim

$442.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Latanoprostene bunod is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by controlling the flow of fluid within the eye to maintain a normal pressure.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. KEITH A SCHRUNK OD provides transparency into local medical care patterns within Denison, IA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.